Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8302 for underactive bladder
NL-OMON48804Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Detrusor hypocontractility comparing ASP8302 with Placebo (2 arms). Primary endpoint: Change from baseline to visit 4 in post-void residual volume after standardized bladder filling. Started Apr 2019; status: active, not recruiting.
02
Drugs
ASP8302
03
Conditions
Detrusor hypocontractility
Beyond the preview
Go deeper on NL-OMON48804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48804.